BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 11022631)

  • 1. The Cape Town experience with haematopoietic stem cell transplantation: the paediatric programme.
    Roux P; Novitzky N
    S Afr Med J; 2000 Aug; 90(8):804-11. PubMed ID: 11022631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI.
    Willemze AJ; Geskus RB; Noordijk EM; Kal HB; Egeler RM; Vossen JM
    Bone Marrow Transplant; 2007 Aug; 40(4):319-27. PubMed ID: 17572715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
    Min CK; Kim DW; Lee JW; Han CW; Min WS; Kim CC
    Haematologica; 2001 Mar; 86(3):303-10. PubMed ID: 11255278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
    Novitzky N; Thomas V; du Toit C; McDonald A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
    Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution.
    Al-Qurashi F; Ayas M; Al Sharif F; Ibrahim E; Sahovic E; Al Mahr M; Chaudhri N; Al Mohareb F; Al Zahrani H; Al Jefri A; Al Omar H; Al Shanqeeti A; Seth P; Aslam M; El Solh H; Aljurf M
    Hematology; 2004 Apr; 9(2):123-9. PubMed ID: 15203867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome.
    Rubin CM; Mick R; Johnson FL
    Bone Marrow Transplant; 1996 Sep; 18(3):533-40. PubMed ID: 8879614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
    Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
    Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
    Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
    N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
    Socié G; Stone JV; Wingard JR; Weisdorf D; Henslee-Downey PJ; Bredeson C; Cahn JY; Passweg JR; Rowlings PA; Schouten HC; Kolb HJ; Klein JP
    N Engl J Med; 1999 Jul; 341(1):14-21. PubMed ID: 10387937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience.
    Farzin A; Davies SM; Smith FO; Filipovich A; Hansen M; Auerbach AD; Harris RE
    Br J Haematol; 2007 Feb; 136(4):633-40. PubMed ID: 17367413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
    Oyekunle AA; Kröger N; Zabelina T; Ayuk F; Schieder H; Renges H; Fehse N; Waschke O; Fehse B; Kabisch H; Zander AR
    Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia.
    Lang P; Teltschik HM; Feuchtinger T; Müller I; Pfeiffer M; Schumm M; Ebinger M; Schwarze CP; Gruhn B; Schrauder A; Albert MH; Greil J; Urban C; Handgretinger R
    Br J Haematol; 2014 Jun; 165(5):688-98. PubMed ID: 24588540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
    Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
    Chaudhury S; Auerbach AD; Kernan NA; Small TN; Prockop SE; Scaradavou A; Heller G; Wolden S; O'Reilly RJ; Boulad F
    Br J Haematol; 2008 Mar; 140(6):644-55. PubMed ID: 18302713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.